The Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, 240 East 38th Street, 12th Floor, New York, NY, 10016, USA.
University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Arch Dermatol Res. 2024 Aug 12;316(8):514. doi: 10.1007/s00403-024-03257-w.
Androgenetic alopecia (AGA) significantly impacts patients' psychological well-being, and treatment options have historically been limited. However, the advent of low-dose oral minoxidil (LDOM) has revolutionized AGA management. This study compares the treatment response and safety of LDOM in patients with AGA alone versus those with AGA unmasked by telogen effluvium. Our findings indicate that LDOM is effective and safe for both groups, showing comparable efficacy and safety profiles. These results support the use of LDOM as a reliable treatment option for AGA, potentially improving patient outcomes and quality of life.
雄激素性脱发（AGA）显著影响患者的心理健康，且历史上的治疗选择有限。然而，低剂量口服米诺地尔（LDOM）的出现彻底改变了 AGA 的治疗管理方式。本研究比较了 LDOM 在单纯 AGA 患者和由休止期脱发诱发的 AGA 患者中的治疗反应和安全性。我们的研究结果表明，LDOM 对这两组患者均有效且安全，具有相似的疗效和安全性特征。这些结果支持将 LDOM 作为 AGA 的可靠治疗选择，可能改善患者的治疗效果和生活质量。
